SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.
JonesTrading 2023 Healthcare Summit
Format: Investor meetings
Location: Miami, FL
Date: October 9-11, 2023
BIO Investor Forum
Format: Corporate presentation and investor meetings
Location: San Francisco, CA
Date: Tuesday, October 17, 2023
Time: 1:15-2:00 P.M. Pacific Time
OPAL Group Family Office & Private Wealth Management Forum West 2023
Format: Corporate presentation and investor meetings
Location: Napa, CA
Date: Thursday, October 19, 2023
Time: 10:50-11:10 P.M. Pacific Time
About Kineta
Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Kineta, Inc.:
Jacques Bouchy
EVP Investor Relations & Business Development
+1 206-378-0400
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
John Mullaly
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.23 |
Daily Change: | 0.02 7.55 |
Daily Volume: | 223 |
Market Cap: | US$2.800M |
April 08, 2025 November 08, 2024 October 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load